Author Archives: Marisa Wexler MS

Recorlev Helps to Keep Cholesterol in Check, LOGICS Trial Data Show

Continuous treatment with Recorlev (levoketoconazole) helped to lower blood cholesterol levels in adults with endogenous Cushing’s syndrome, according to data from the Phase 3 LOGICS trial. Scientists at Xeris Biopharma, the company that markets Recorlev, presented the findings in the poster “Levoketoconazole in the Treatment of Endogenous…

High Copeptin Levels After Surgery May Be Linked to Remission

High levels of the hormone precursor copeptin following surgery might be associated with remission in people with Cushing’s disease who do not later develop water balance disorders, new data indicate. However, the scientists stressed the need for further research on this potential biomarker, noting that copeptin levels after surgery…

Europe Awaits Proposed New Framework for Sharing Health Data

The European Commission is expected to propose a new governing framework for health data next month, called the European Health Data Space (EHDS), with the aim of connecting national health systems to facilitate secure and efficient transfer of data across systems in different European nations. The move is expected to…

Technique Speeds Adrenal Gland Recovery After Surgery

A new surgical technique pioneered at the Carling Adrenal Center in Florida allows for faster recovery of adrenal gland function after removal of an adrenal tumor. The adrenal glands are a pair of small, triangular organs located above the kidneys. They are responsible for producing a number of hormones that…

Low Vitamin D Levels in Patients Improved With Supplements

People with Cushing’s disease have a high risk of being deficient in vitamin D, but taking supplements can improve those levels, a new study indicates. Results also showed that lower vitamin D levels are associated with higher levels of cortisol, a stress hormone that is elevated in Cushing’s. The…

Corcept Will Seek FDA Approval of Relacorilant in 2023

Corcept Therapeutics is on track to ask the U.S. Food and Drug Administration (FDA) to approve the investigational therapy relacorilant to treat Cushing’s syndrome by the middle of next year, the company announced. Cushing’s syndrome is characterized by excessive levels of the stress hormone cortisol, which causes a range of…

PANTHERx Rare Pharmacy to Distribute Recorlev Therapy in US

Xeris Pharmaceuticals has selected the specialty pharmacy PANTHERx Rare to distribute Recorlev (levoketoconazole), the company’s therapy that was recently approved to treat adults with endogenous Cushing’s syndrome in whom surgery is not possible or not effective. “PANTHERx is proud to partner with Xeris to address the needs of adults…

Sparrow Cleared to Start Phase 2 Trial of SPI-62 Early Next Year

Sparrow Pharmaceuticals is gearing up for the start of a Phase 2 trial that will assess the safety and effectiveness of the company’s experimental medicine SPI-62 in people with Cushing’s disease. The U.S. Food and Drug Administration has cleared Sparrow’s investigational new drug application (IND), giving the company…